Evidence map›Paper›PMID 39599830›Full record

ArticleViruses2024

Spectrum of Non-Nucleoside Reverse Transcriptase Inhibitor-Associated Drug Resistance Mutations in Persons Living with HIV-1 Receiving Rilpivirine.

Pavithra Nagarajan, Jinru Zhou, Giulia Di Teodoro, Francesca Incardona, Carole Seguin-Devaux, Rolf Kaiser, Ana B Abecasis, Perpetua Gomes, Kaiming Tao, Maurizio Zazzi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Pavithra NagarajanDivision of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Jinru ZhouDivision of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Giulia Di TeodoroEuResist Network GEIE, 00152 Rome, Italy.ORCID 0000-0002-0418-0067
Francesca IncardonaEuResist Network GEIE, 00152 Rome, Italy.ORCID 0000-0002-7386-8551
Carole Seguin-DevauxDepartment of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-0636-5222
Rolf KaiserInstitute of Virology, University of Cologne, 50931 Cologne, Germany.ORCID 0000-0002-2640-2548
Ana B AbecasisGlobal Health and Tropical Medicine, LA-REAL, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, 1349-008 Lisbon, Portugal.ORCID 0000-0002-3903-5265
Perpetua GomesLaboratório de Biologia Molecular, Serviço de Patologia Clínica, Unidade Local de Saúde Lisboa Ocidental, Hospital Egas Moniz, 1349-019 Lisbon, Portugal.ORCID 0000-0003-3271-8255
Kaiming TaoDivision of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-8731-1271
Maurizio ZazziDepartment of Medical Biotechnology, University of Siena, 53100 Siena, Italy.ORCID 0000-0002-0344-6281
Robert W ShaferDivision of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-2513-2643
EuResist Network

Funding

HIV Drug Resistance DatabaseR24AI136618 · NIAID · STANFORD UNIVERSITY · PI ROBERT William SHAFER · 2018 to 2026
$7.3M
NIAID NIH HHS R24 AI136618NIH HHS 2R24AI13661806
6 · The paper itself

Abstract

introductionFew data are currently available on the nonnucleoside reverse transcriptase (RT) inhibitors (NNRTI) resistance mutations selected in persons living with HIV-1 (PLWH) who develop virological failure while receiving rilpivirine (RPV).

methodsWe analyzed pooled HIV-1 RT genotypic data from 280 PLWH in the multicenter EuResist database and 115 PLWH in the Stanford HIV Drug Resistance Database (HIVDB) who received RPV as their only NNRTI.

resultsAmong the 395 PLWH receiving RPV, 180 (45.6%) had one or more NNRTI-associated DRMs. Overall, 44 NNRTI-associated DRMs were identified, including 26 that occurred in two or more PLWHs. Seven mutations had a prevalence ≥10% among the 180 PLWH with one or more NNRTI-associated DRM: E138K (32.2%), V90I (25.0%), K101E (17.8%), Y181C (17.2%), E138A (13.9%), H221Y (12.2%), and K103N (10.6%). Y181C was significantly more likely to co-occur with K101E, V179F, H221Y, and M230L. Ten novel non-polymorphic mutations at known NNRTI-associated mutation positions were also identified, usually in just one PLWH: L100F, V108A, T139I, P225S, M230V, Y232C, and T240A/I/M/S.

conclusionsOur analysis extends the spectrum of mutations emerging in PLWH receiving RPV. Additional phenotypic characterization of RPV-selected mutations is necessary to better understand their biological and possible clinical significance.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHIV-1HIV InfectionsHIV Reverse TranscriptaseMutationReverse Transcriptase InhibitorsRilpivirineAdultFemaleGenotypeHumansMaleMiddle AgedAnti-HIV AgentsHIV Reverse Transcriptasereverse transcriptase, Human immunodeficiency virus 1Reverse Transcriptase InhibitorsRilpivirineHIV-1 drug resistancenon-nucleoside reverse transcriptase inhibitorsrilpivirine

Identifiers

PMID39599830
PMCPMC11599002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.